secwatch.observer — SEC 8-K summary
======================================

Issuer:     Intellia Therapeutics, Inc. (NTLA)
CIK:        0001652130
Form:       8-K
Filed at:   2024-02-01T23:59:59+00:00
Accession:  0000950170-24-009776
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Intellia reports NTLA-2002 Phase 1 data: 95% reduction in HAE attacks; 9/10 attack-free
--------------------------------------------------------------------------------

- Single dose of NTLA-2002 led to 95% mean reduction in monthly HAE attack rate across all 10 patients.
- Nine of 10 patients remained completely attack-free following the 16-week primary observation period.
- All 6 patients who discontinued long-term prophylaxis reported no attacks since stopping.
- NTLA-2002 well-tolerated; most common adverse events were mild infusion reactions and fatigue.
- Global pivotal Phase 3 study planned for H2 2024 subject to regulatory feedback.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1652130/000095017024009776/0000950170-24-009776-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1652130/000095017024009776/ntla-20240131.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-009776

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer